Target intelligence / Profile preview

NAD+-II riboswitch

Target
NAD+-II riboswitch
Molecular classification
Noncoding RNA, Riboswitch
01

Overview

The NAD+-II riboswitch is a structured noncoding RNA domain discovered in bacterial mRNAs that serves as a ligand-activated genetic regulatory element. It specifically recognizes and binds nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR). This riboswitch is termed “NAD+-II” (or class II NAD+ riboswitch) to distinguish it from the NAD+-I riboswitch. It features one aptamer domain (unlike the tandem arrangement in NAD+-I)[6]. Structural studies reveal that it contains complex tertiary RNA folds and forms two distinct ligand-binding pockets that can each bind one ligand molecule predominantly via the nicotinamide moiety of NAD+ or its derivatives[1][3][2]. The NAD+-II riboswitch is typically found upstream of pnuC genes, which encode NR transporters crucial for NAD+ biosynthesis in bacteria and is thus implicated in the regulation of NAD+ transporter expression[5]. While this riboswitch is functionally important for bacterial metabolism and gene regulation, it is not classified as a therapeutic target (receptor, enzyme, transporter, etc.), nor is it currently associated with human disease, pharmacological intervention, or biomarker utility in clinical settings[5][3]. Its value resides in regulating cofactor metabolism and as a model for RNA structure and ligand recognition[3].

Other names
NAD-II riboswitchclass-II NAD+ riboswitchpnuC motifNAD+-II RNA
02

Biological functions

Gene regulationMetabolic sensingRNA-mediated control of NAD+ metabolism
03

Disease associations

No direct disease association; fundamental regulatory RNA in bacteria

Beyond the preview

Go deeper on NAD+-II riboswitch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAD+-II riboswitch.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call